Skip to content

Emeryville, CA, December 4, 2023 – FlemingMartin is pleased to announce that Kyverna Therapeutics, a clinical-stage company dedicated to developing life changing cell therapies for autoimmune disease, has hired Devin Murray as their Senior Vice President of Partnerships and Alliance Management.

Devin is a biotech industry executive with a passion for cell therapy and 25 years of diverse experience across the business development, alliance management, strategy, sales, marketing, and operations functions. Over the course of his career, Devin has played an integral role in securing and expanding key partnerships in the U.S., Europe, and Asia, aligning cross-functional teams, and building out commercial capabilities for growing organizations. Among his array of achievements, Devin led the development of the allogeneic T-cell management platform at Atara Bio (NASDAQ: ATRA) and he played an instrumental role in multiple successful product launches at both Exelixis (NASDAQ: EXEL) and Amgen (NASDAQ: AMGN). Most recently, Devin served as the Chief Operating Officer at Cellevolve Bio, a cell therapy company focused on translating early stage clinical therapies into commercially available treatments for neglected diseases.

Devin earned his MBA from Northwestern University’s Kellogg School of Management, and he received his BS in Chemical Engineering from Drexel University.

Kyverna Logo

Headquartered in Emeryville, California, Kyverna Therapeutics is a clinical-stage company focused on developing life changing cell therapies that can free patients from the siege of autoimmune disease.


Fm Logo For Wp FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Venture Capital Firms, and CEOs to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.